Signature for Precise Chemosensitivity Prediction in PDAC
NCT ID: NCT06461598
Last Updated: 2024-06-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
365 participants
OBSERVATIONAL
2018-01-01
2021-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical and Multiomics Study of First-line Chemotherapy for Advanced Pancreatic Cancer
NCT05168254
A Longitudinal, Observational Biomarker Study in Pancreatic Cancer Patients Receiving Chemotherapy
NCT04281511
Influence Factors of PD-1 Therapeutic Efficacy in Advanced Pancreatic Cancer
NCT05201729
Clinical Efficacy of QYHJ and Standard Chemotherapy in the Treatment of Advanced Pancreatic Cancer
NCT05840341
QL1706 Plus Chemotherapy With AG Regime as First-line Treatment of Advanced PDAC
NCT06750861
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Training cohort
Chemotherapy
All adjuvant chemotherapy for nonmetastatic PDAC was gemcitabine-based (Cycle \>= 1).
Validation cohort
Chemotherapy
All adjuvant chemotherapy for nonmetastatic PDAC was gemcitabine-based (Cycle \>= 1).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Chemotherapy
All adjuvant chemotherapy for nonmetastatic PDAC was gemcitabine-based (Cycle \>= 1).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* complete clinicopathologic and follow-up data
* availability of formalin-fixed paraffin-embedded (FFPE) specimens of resected primary tumor and hematoxylin and eosin slides with invasive tumor components
Exclusion Criteria
* any anticancer therapy prior to resection or adjuvant radiotherapy
* metastatic cases
* major postsurgical complications with Clavien-Dindo Grade ≥2
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ruijin Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
lei huang
PI
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ruijin Hospital
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ChemoResist-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.